Denosumab and dental implant healing

Dental implant success depends on osseointegration: bone growing into the surface of the titanium implant. This process requires active bone remodeling. Denosumab slows that remodeling by blocking RANK ligand, which is the signal that activates osteoclasts. The intuition is that denosumab would impair osseointegration, but current American Dental Association guidance does not consider osteoporosis antiresorptive therapy a contraindication to dental implants, though long-term comparative evidence is limited.

The bigger concern, as with bisphosphonates, is MRONJ at the surgical site. Implant placement involves osteotomy (drilling into the jaw bone), which is meaningful surgical trauma. In patients on cancer-dose denosumab (Xgeva), current American Association of Oral and Maxillofacial Surgeons and American Dental Association guidance consider dental implants contraindicated during therapy, and implant planning is deferred and coordinated with the oncology and oral-surgery teams. In patients on osteoporosis-dose denosumab (Prolia), MRONJ remains uncommon and implants are more commonly placed, with careful planning and close follow-up.

Timing conversations are different for denosumab than for bisphosphonates because the drug's effect reverses within months of stopping. There is also a specific safety consideration: stopping or substantially delaying denosumab can trigger rebound bone loss and increase fracture risk, including the risk of multiple vertebral fractures. For that reason, any timing of Prolia around implant surgery is a clinician-managed decision and is not something a patient or a dentist should adjust on their own.